Jiangsu Medomics Medical Technology Co., Ltd.,
Free Member
Business license
  • Main Products

    Covid-19 & Influenza A/B Antigen Combo Rapid Test Kit (LFIA) ,KPC/IMP/NDM/VIM/OXA-48 Combo Test Kit (LFIA) ,Gynecology antigen Combo Test Kit ,Medomics High-Throughput Autostainer Machine
  • Main Markets

    South America , Eastern Europe , Southeast Asia , Africa , Oceania , Mid East , Eastern Asia , Western Europe , Central America , Northern Europe , Southern Europe , South Asia , Domestic Market

Contact Supplier

Jiangsu Medomics Medical Technology Co., Ltd.,

Jiangsu Medomics Medical Technology Co., Ltd.,

Your inquiry content must be betw-een 20 to 5000 characters.Send N-ow.

Please enter Your valid email add-ress.

Please enter a correct verification code.

Jiangsu Medomics Medical Technology Co., Ltd., AIBot OnlineThis conversation is AI-generated. Contact manufacturer before transaction to confirm info.
  • sales
    Welcome to my shop! Glad to serve you!Please send your question!

Please enter a correct verification code.

Best Products about

Company Profile

  • Jiangsu Medomics Medical Technology Co., Ltd.,
  • Jiangsu Medomics Medical Technology Co., Ltd.,
  • Jiangsu Medomics Medical Technology Co., Ltd.,
  • Jiangsu Medomics Medical Technology Co., Ltd.,
  • Jiangsu Medomics Medical Technology Co., Ltd.,
  • Jiangsu Medomics Medical Technology Co., Ltd.,

Jiangsu Medomics Medical Technology Co., Ltd.,

  • Covid-19 & Influenza A/B Antigen Combo Rapid Test Kit (LFIA) ,KPC/IMP/NDM/VIM/OXA-48 Combo Test Kit (LFIA) ,Gynecology antigen Combo Test Kit ,Medomics High-Throughput Autostainer Machine
  • South America, Eastern Europe, Southeast Asia, Africa, Oceania, Mid East
Business license
Contact Now
Chat Now

Jiangsu Medomics Medical Technology Co., Ltd., founded in October 2017, is located at Biotech and Pharmaceutical Valley of the National Jiangbei New Area, Nanjing, Jiangsu Province. It is an international high-tech enterprise driven by innovation in the area of medical devices R&D, production and sales. Medomics focuses on diagnosis of microorganisms, tumors and some rare diseases, mainly engaged in the research and development, production and sales of in vitro diagnostic reagents and automatic instruments.  

Medomics owns two R&D centers in China and the US, independent intellectual property rights of fluorescent staining technology, protein labeling technology, time-resolved immunofluorescence detection technology, image processing and analysis technology and other innovative technology platforms, as well as a total of more than 2,000 square meters of GMP purification production workshop that meets the product standards of FDA, CE and CFDA. Medomics also has a multidisciplinary expert team with abundant  experience in the industry, including senior experts in immunology, microbiology, applied physics, polymer materials, medical imaging, optical systems, etc. The members of the technical team are led by doctors from many famous institutions, such as Osaka University, North Carolina University, University of Nebraska Lincoln, Zhejiang University, Sichuan University and other institutions.

At the very beginning of COVID-19 on early 2020, Medomics developed IgM/IgG antibody detecting kit with the team of Zhong Nanshang. And Medomics published the first research paper on international journal together with State Key Laboratory of Respiratory Disease (National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health). The detecting kit was validated by CDC, Harvard Medical School and Columbia University Irving Medical Center etc. Until May 2020, the kit has been exported to dozens of countries and areas, making great help against SARS-Cov-2.

At present, Medomics’s series products of SARS-Cov-2 detection have been developed according to ISO 13485 Quality System and European CE Certification.


View All >

Contact Supplier

  • Jiangsu Medomics Medical Technology Co., Ltd.,
  • Your inquiry content must be between 20 to 5000 characters.
  • Please enter a correct verification code.